Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Summary

This was a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone in adults with relapsed/refractory multiple myeloma. The primary objective of this study was to evaluate the antitumor efficacy of ONC201. Note: This study was completed by predecessor company, Oncoceutics, Inc.

Timeline

Start

2017-04-19

Primary completion

2019-09-17

Completion

2019-12-16

Outcome

Outcome not reported

Stopped: “This study was terminated due to a change in corporate priorities. The decision to terminate the study was not based on any safety concerns.”

Drugs

Indications